AVIR Stock Analysis: Buy, Sell, or Hold?
AVIR - Atea Pharmaceuticals, Inc. Common Stock
$5.71
0.04 (0.71%)
▲
5d:
-2.73%
30d:
-6.39%
90d:
+65.51%
BUY
MODERATE Confidence
Analysis Updated: Apr 13, 2026 12:00 AM ET
Earnings: May 11, 2026
27d
Get Alerted When AVIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AVIR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AVIR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AVIR is currently trading at $5.71, which is considered fair relative to its 30-day fair value range of $5.42 to $6.06.
Technical Outlook: Technically, AVIR is in a strong uptrend. Immediate support is located at $5.03, while resistance sits at $6.29.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+54.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AVIR is in a strong uptrend. Immediate support is located at $5.03, while resistance sits at $6.29.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.83 (+54.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$5.42 -
$6.06
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.7% below Wall St target ($8.83)
Fair Price Analysis
30-Day Fair Range
$5.42 -
$6.06
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$5.03
Resistance Level
$6.29
Current Trend
Strong Uptrend
Technical data as of
Apr 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.12
Wall Street Target
$8.83
(+54.7%)
Revenue Growth (YoY)
295.2%
Earnings Growth (YoY)
264.1%
Share & Embed Analysis
Last updated: April 13, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$408 | 57 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$224 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 60 BUY |